Table 1 Omicron BA.1/2 infection attack rate (AR) in rural and urban cohorts of South Africa based on 905 participants with complete serologic information (75% of the total 1200 participants)
From: Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa
Rural (478) | Urban (427) | |
|---|---|---|
Characteristics | n/N (AR%) | n/N (AR%) |
Age group, in years | ||
0–4 | 42/64 (65.6) | 19/37 (51.4) |
5–12 | 129/185 (69.7) | 76/113 (67.3) |
13–18 | 39/59 (66.1) | 46/67 (68.7) |
19–39 | 44/64 (68.8) | 50/77 (64.9) |
40–59 | 37/71 (52.1) | 43/91 (47.3) |
60+ | 18/35 (51.4) | 14/42 (33.3) |
Sex | ||
Male | 116/171 (67.8) | 108/188 (57.4) |
Female | 193/307 (62.9) | 140/239 (58.6) |
Household size (no. individuals) | ||
3–5 | 129/190 (67.9) | 121/212 (57.1) |
6–8 | 91/156 (58.3) | 84/148 (56.8) |
9–12 | 71/99 (71.7) | 31/50 (62.0) |
13+ | 18/33 (54.5) | 12/17 (70.6) |
HIV status | ||
Negative | 257/392 (65.6) | 201/345 (58.3) |
PLWH* | 39/63 (61.9) | 41/71 (57.7) |
Unknown | 13/23 (56.5) | 6/11 (58.2) |
SARS-CoV-2 immunity status | ||
Naive | 117/144 (81.3) | 71/94 (75.5) |
Janssen Ad26.COV2.S (1dose) | 9/11 (81.8) | 2/2 (100) |
Pfizer–BioNTech BNT162b2 (1st dose) | 5/10 (50.0) | 2/3 (66.7) |
Pfizer–BioNTech BNT162b2 (2nd dose) | 3/5 (60.0) | 6/11 (54.5) |
Prior infection (D614G) | 20/27 (74.1) | 47/67 (70.2) |
Prior infection (Beta) | 50/69 (72.5) | 56/92 (60.9) |
Prior infection (Delta) | 81/149 (54.4) | 33/61 (54.1) |
Hybrid immunity† | 19/41 (46.3) | 15/47 (31.9) |
Repeated infections | 4/19 (21.1) | 10/37 (27.0) |
Rest‡ | 1/3 (33.3) | 6/13 (46.2) |
